Compare MG & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MG | AURA |
|---|---|---|
| Founded | 1978 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 642.4M | 631.6M |
| IPO Year | 2008 | 2021 |
| Metric | MG | AURA |
|---|---|---|
| Price | $20.21 | $7.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | ★ $21.18 | $16.60 |
| AVG Volume (30 Days) | 347.1K | ★ 741.8K |
| Earning Date | 11-27-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.51 | N/A |
| Revenue | ★ $700,970,000.00 | N/A |
| Revenue This Year | $3.15 | N/A |
| Revenue Next Year | $5.40 | N/A |
| P/E Ratio | $39.63 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.13 | $4.73 |
| 52 Week High | $21.92 | $9.54 |
| Indicator | MG | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 43.61 | 56.99 |
| Support Level | $20.06 | $6.65 |
| Resistance Level | $21.77 | $7.83 |
| Average True Range (ATR) | 0.11 | 0.41 |
| MACD | -0.04 | 0.09 |
| Stochastic Oscillator | 30.61 | 59.56 |
MISTRAS Group Inc provides asset protection solutions and systems. The company evaluates the structural integrity and reliability of critical energy, industrial, and public infrastructure. The company's three operating segments are North America, International, and Products and Systems, of which key revenue is derived from the North America segment. The North America segment provides asset protection solutions, including NDT, inspection, and mechanical and engineering services, along with software, digital, and data services.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.